Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.61 |
| ▸ | CNR1 | P21554 | 10/20 | 0.50 |
| ▸ | CNR2 | P34972 | 3/20 | 0.47 |
| ▸ | CDC7 | O00311 | 1/20 | 0.46 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.45 |
| ▸ | VCP | P55072 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1055067 | 0.92 | OPRM1 (0.57) | OPRM1CNR1CNR2CYP1A2CYP2C19 | |
| SCHEMBL4295570 | 0.82 | OPRM1 (0.51) | OPRM1CNR1CNR2BRD4CYP1A2 | |
| SCHEMBL4309421 | 0.82 | CNR1 (0.58) | OPRM1CNR1CNR2HTR2AKDM4E | |
| SCHEMBL4291997 | 0.77 | BRD4 (0.47) | OPRM1CNR1BRD4CYP1A2CYP2C19 | |
| SCHEMBL1054261 | 0.77 | BRD4 (0.47) | OPRM1CNR1BRD4CYP1A2CYP2C19 | |
| SCHEMBL13429265 | 0.77 | FLT3 (0.43) | OPRM1CDC7DBF4VCPALDH1A1 | |
| SCHEMBL1053495 | 0.75 | JAK1 (0.49) | OPRM1CNR1ALDH1A1ALOX15 | |
| SCHEMBL4292193 | 0.73 | DRD2 (0.57) | ALDH1A1KDM4E | |
| SCHEMBL1054619 | 0.71 | KAT2B (0.50) | OPRM1BRD4ALDH1A1ALOX15HTR2A | |
| SCHEMBL29170463 | 0.69 | CYP1A2 (0.56) | CYP1A2CYP2C19TNKS2ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106536509-B | Novel compounds as dual inhibitors of histone methyltransferase and DNA methyltransferase | 基础应用医学研究基金会 | 2020-06-09 | — | — | CN | disclosed |
| US-7875624-B2 | administering a cancer patient 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one in the treatment of disorders relating to cell adhesion and metastatic processes; for monitoring the effects of drug by measuring the levels of ICAM, VCAM, or E-selectin in the patient | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | BARSANTI PAUL A | 2009-11-12 | — | — | US | disclosed |
| US-20050239825-A1 | Modulation of inflammatory and metastatic processes | CHIRON CORPORATION | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | GAA, ALPI, IL4I1 | OPRM1 2790/4885CNR1 4087/4885CNR2 3723/4885 |
| US-20050239825-A1 | Modulation of inflammatory and metastatic processes | VCAM1, EPCAM, ICAM1 | OPRM1 223/4885CNR1 2983/4885CNR2 2846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.